WO2023125846A1 - Composé pour prévenir et traiter une infection à coronavirus, conjugué de celui-ci et méthode associée - Google Patents

Composé pour prévenir et traiter une infection à coronavirus, conjugué de celui-ci et méthode associée Download PDF

Info

Publication number
WO2023125846A1
WO2023125846A1 PCT/CN2022/143566 CN2022143566W WO2023125846A1 WO 2023125846 A1 WO2023125846 A1 WO 2023125846A1 CN 2022143566 W CN2022143566 W CN 2022143566W WO 2023125846 A1 WO2023125846 A1 WO 2023125846A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
cycloalkyl
deuterium
halogen
Prior art date
Application number
PCT/CN2022/143566
Other languages
English (en)
Chinese (zh)
Inventor
彭程
宋国伟
武进
钱梦飞
宋治东
袁帅
凌炜康
高凡
袁海卿
邬征
Original Assignee
苏州爱科百发生物医药技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州爱科百发生物医药技术有限公司 filed Critical 苏州爱科百发生物医药技术有限公司
Priority to CN202280085522.9A priority Critical patent/CN118434728A/zh
Publication of WO2023125846A1 publication Critical patent/WO2023125846A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • the present invention relates to the field of medicine, in particular to a compound and its conjugate and method for preventing and treating coronavirus infection.
  • the present invention relates to compounds and methods for inhibiting viral replication activity, comprising contacting a SARS-CoV-2 related 3C-like (3CL) protease with a therapeutically effective amount of a SARS-CoV-2 related 3C-like protease inhibitor.
  • the present invention also relates to methods of treating coronavirus disease 2019 (COVID-19) in patients by providing them with a therapeutically effective amount of a SARS-CoV-2-associated 3C-like protease inhibitor.
  • the present invention also relates to a method of treating COVID-19 in a patient comprising administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a SARS-CoV-2 associated 3C-like protease inhibitor agent.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • SARS-CoV-2 has 79% homology with SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus), the causative agent of the SARS epidemic in 2002-2003, and with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) There is 50% homology.
  • Symptoms of COVID-19 include fever, cough, shortness of breath, fatigue, headache, loss of smell, nasal congestion, sore throat, expectoration, muscle or joint pain, chills, nausea, vomiting and diarrhea.
  • symptoms include difficulty waking up, confusion, bluish face or lips, coughing up blood, decreased white blood cells, and kidney failure.
  • Complications include pneumonia, viral sepsis, acute respiratory distress syndrome, and renal failure.
  • the SARS-CoV-2 coronavirus belongs to the Coronaviridae family and is a single-stranded positive-sense RNA virus with an envelope. Similar to other known coronaviruses, the SARS-CoV-2 coronavirus also undergoes several processes such as adsorption, penetration, shelling, biosynthesis, assembly and release of progeny viruses to complete the proliferation of progeny viruses.
  • SARS-CoV-2 coronavirus infection of host cells begins with the binding of the spike glycoprotein on the surface of the virus envelope to the receptors on the surface of the host cell, followed by membrane fusion, and the virus enters the host cell under the action of cell organelles such as lysosomes , to release the genetic material of the virus, single-stranded positive-sense RNA, which is translated into a polyprotein under the action of protein synthesis elements such as mitochondria and ribosomes of the host cell, and necessary raw materials.
  • cell organelles such as lysosomes
  • the two major components of the SARS-CoV-2 coronavirus Essential cysteine proteases papain-like protease (PL pro) and 3C-like protease (3C-like protease, 3CL pro) cut and process polyprotein precursors at specific sites, resulting in multiple pairs of viral life Periodically important nonstructural proteins. Under the action of these non-structural proteins, viral RNA replicates progeny viral nucleic acid substances, and translates a large amount of required structural proteins to complete the assembly and release of progeny viruses.
  • Any link or key enzyme in the life cycle of SARS-CoV-2 coronavirus-infected cells can be used as a research target for antiviral drugs, such as cysteine proteases PL pro and 3CL pro, which hydrolyze and cut polyprotein precursors, are responsible for RNA polymerase that completes the replication of the genetic material of progeny viruses, etc.
  • antiviral drugs such as cysteine proteases PL pro and 3CL pro, which hydrolyze and cut polyprotein precursors, are responsible for RNA polymerase that completes the replication of the genetic material of progeny viruses, etc.
  • 3CL protease (3chymotrypsin-like protease, 3CL pro), also known as the main protease (M pro), is the key protease in the process of hydrolyzing the polyproteins pp1a and pp1ab after the translation of coronavirus RNA to produce multiple non-structural proteins. Replication and infection are very important. Inhibiting the catalytic function of 3CL protease can effectively inhibit the cleavage of viral polyprotein precursors, block virus replication, and inhibit the generation of progeny viruses.
  • 3CL pro belongs to cysteine protease, which is a key protease that catalyzes the proteolysis of single positive-strand RNA virus precursor, and plays an important role in the replication activity of coronaviruses such as SARS-CoV-2. Therefore, 3CL pro is currently recognized as an ideal target for the development of anti-coronavirus drugs.
  • the threat to public health is particularly serious.
  • the coronavirus is highly contagious, and current research suggests that it can be spread by asymptomatic carriers or pre-symptomatic people.
  • the early development of the disease is very slow, and carriers are often unaware that they are infected, leading them to expose many people to the virus.
  • the combination of the ease with which COVID-19 spreads and the high rates of hospitalization and mortality among patients make viral infection a significant public health risk, especially in those without the healthcare system to provide supportive care for patients at pandemic levels nation.
  • Pfizer's oral drug Paxlovid has been authorized by the FDA for emergency use.
  • 3CLpro inhibitor nirmatrelvir
  • CYP3A inhibitor ritonavir
  • SARS-CoV-2 coronavirus 3CL pro an oral antiviral drug with novel structure, low toxicity and high efficiency, more stable and independent intellectual property rights has been developed to meet the clinical needs of patients infected with SARS-CoV-2 coronavirus at home and abroad. great social significance.
  • SARS-CoV-2 coronavirus 3CL protease for the prevention and treatment of pneumonia caused by SARS-CoV-2 coronavirus infection.
  • the present invention provides a class of inhibitors against SARS-CoV-2 coronavirus 3CL protease, which can be used to prevent and treat pneumonia caused by SARS-CoV-2 coronavirus infection.
  • the present invention provides the following technical solutions:
  • the present invention provides a compound represented by formula I or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, conjugates and pharmaceutically acceptable salts:
  • the compound provided by the invention has good activity of inhibiting SARS-CoV-2 coronavirus 3CL protease, and can be used for preventing and treating pneumonia caused by SARS-CoV-2 coronavirus infection.
  • the present invention provides a compound represented by formula I or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, conjugates and pharmaceutically acceptable salts:
  • n are each independently any integer from 0 to 4.
  • R 3 is selected from cyano, aldehyde, -(CO)CH 3 and -(CO)CF 3 ;
  • Each R is independently selected from hydrogen, deuterium, unsubstituted or selected from cyano, amino, hydroxyl, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl and C 1-6 alkyl, C 3-7 cycloalkyl and 3-7 heterocycloalkyl substituted by substituents of 5-10 membered heteroaryl;
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • any R 4 and R 5 and their connected C atoms and N atoms form a substituted or unsubstituted 5-7 membered ring
  • the replacement is 1-4 selected from hydrogen, deuterium, cyano, halogen, trifluoro Substituents of methyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl and 5-10 membered heteroaryl, or 5-7 membered ring
  • the substituent and the 5-7 membered ring form a ring;
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • any R 4 and R 6 and their connected C atoms and N atoms form a substituted or unsubstituted 5-7 membered ring, and the substitution is 1-4 selected from hydrogen, deuterium, cyano, halogen, tri Substituents of fluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl and 5-10 membered heteroaryl, or the 5-
  • the two substituents of the 7-membered ring form the same carbon atom or two adjacent carbon atoms and are deuterated by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy and C 1-6 deuterated alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • R 9 is selected from substituted or unsubstituted C 1-6 alkyl, C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 1-6 alkylamino, C 1-6 alkoxy, C 3-7 cycloalkoxy, C 3-7 cycloalkylamino, 3-7 heterocycloalkoxy, C 3-7 heterocycloalkylamino, C 6-10 aryl, C 6-10 aryl Baseoxy, 5-10 membered heteroaryl, 6-14 membered spiroheterocyclic group, 5-11 membered bridged heterocyclic group, -NH-C(O)-C 1-6 alkyl, -NH-C( O)-NH-C 1-6 alkyl and 4-11 membered fused heterocyclic groups, the replacement is 1-4 selected from hydrogen, deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl , trifluoromethoxy, by 1-4 selected from hydrogen, deuterium,
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 3 is selected from cyano, aldehyde, -(CO)CH 3 and -(CO)CF 3 .
  • R3 is selected from cyano and -(CO) CH3 .
  • R is selected from cyano.
  • any of R 4 and R 6 and their attached C and N atoms form a substituted or unsubstituted 5-6 membered ring.
  • any of R 4 and R 6 and their attached C and N atoms form substituted or unsubstituted pyrrolidinyl and piperidinyl groups.
  • the substitution is by 1-4 selected from hydrogen, deuterium, cyano, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkane Oxygen, C 6-10 aryl and 5-10 membered heteroaryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl and C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the two substituents of the 5-6 membered ring form the same carbon atom or two adjacent carbon atoms by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy A C 3-7 cycloalkyl group substituted by a C 1-6 deuterated alkyl substituent.
  • the two substituents of the 5-6 membered ring form the same carbon atom or two adjacent carbon atoms by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy A C 3-5 cycloalkyl group substituted by a C 1-6 deuterated alkyl substituent.
  • the two substituents of the 5-6 membered ring form the same carbon atom or two adjacent carbon atoms by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy Cyclopropyl and cyclobutyl substituted by C 1-6 deuterated alkyl substituents.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • m is any integer from 0 to 3.
  • n is any integer from 0-2.
  • n is any integer from 0-1.
  • m is 0.
  • n is any integer from 0 to 3.
  • n is any integer from 0-2.
  • n is any integer from 0-1.
  • n 1
  • the present invention provides a compound represented by formula I-1 or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, conjugates and pharmaceutically acceptable salts:
  • n are each independently any integer from 0 to 4.
  • R 3 is selected from cyano, aldehyde, -(CO)CH 3 and -(CO)CF 3 ;
  • Each R is independently selected from hydrogen, deuterium, unsubstituted or selected from cyano, amino, hydroxyl, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl and C 1-6 alkyl, C 3-7 cycloalkyl and 3-7 heterocycloalkyl substituted by substituents of 5-10 membered heteroaryl;
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • any R 4 and R 5 and their connected C atoms and N atoms form a substituted or unsubstituted 5-7 membered ring
  • the replacement is 1-4 selected from hydrogen, deuterium, cyano, halogen, trifluoro Substituents of methyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl and 5-10 membered heteroaryl, or 5-7 membered ring
  • the substituent and the 5-7 membered ring form a ring;
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • any R 4 and R 6 and their connected C atoms and N atoms form a substituted or unsubstituted 5-7 membered ring, and the substitution is 1-4 selected from hydrogen, deuterium, cyano, halogen, tri Substituents of fluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 6-10 aryl and 5-10 membered heteroaryl, or the 5-
  • the two substituents of the 7-membered ring form the same carbon atom or two adjacent carbon atoms and are deuterated by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy and C 1-6 deuterated alkyl
  • R 8 is selected from hydrogen, deuterium, C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • Ring A and ring B are each independently selected from substituted or unsubstituted C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, 6-14 Member spiroheterocyclyl, 5-11 member bridging heterocyclyl and 4-11 member condensed heterocyclyl; the replacement is 1-4 selected from hydrogen, deuterium, cyano, amino, hydroxyl, halogen, trifluoro Substituents of methyl, trifluoromethoxy, C 1-6 alkyl and C 6-10 aryl.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 3 is selected from cyano, aldehyde, -(CO)CH 3 and -(CO)CF 3 .
  • R3 is selected from cyano and -(CO) CH3 .
  • R is selected from cyano.
  • any of R 4 and R 6 and their attached C and N atoms form a substituted or unsubstituted 5-6 membered ring.
  • any of R 4 and R 6 and their attached C and N atoms form substituted or unsubstituted pyrrolidinyl and piperidinyl groups.
  • the substitution is by 1-4 selected from hydrogen, deuterium, cyano, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkane Oxygen, C 6-10 aryl and 5-10 membered heteroaryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl and C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the two substituents of the 5-6 membered ring form the same carbon atom or two adjacent carbon atoms by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy A C 3-7 cycloalkyl group substituted by a C 1-6 deuterated alkyl substituent.
  • the two substituents of the 5-6 membered ring form the same carbon atom or two adjacent carbon atoms by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy A C 3-5 cycloalkyl group substituted by a C 1-6 deuterated alkyl substituent.
  • the two substituents of the 5-6 membered ring form the same carbon atom or two adjacent carbon atoms by hydrogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy Cyclopropyl and cyclobutyl substituted by C 1-6 deuterated alkyl substituents.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • m is any integer from 0 to 3.
  • n is any integer from 0-2.
  • n is any integer from 0-1.
  • m is 0.
  • n is any integer from 0 to 3.
  • n is any integer from 0-2.
  • n is any integer from 0-1.
  • n 1
  • Ring A is selected from substituted or unsubstituted C 3-7 cycloalkyl and 3-7 membered heterocycloalkyl.
  • ring A is selected from substituted or unsubstituted C 3-5 cycloalkyl and 3-5 membered heterocycloalkyl.
  • Ring A is selected from substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, and morpholinyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl and C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O and S.
  • Ring B is selected from substituted or unsubstituted phenyl, furyl, thienyl, pyridyl, pyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, tri Azolyl and tetrazolyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl, C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the present invention provides a compound represented by formula I-2 or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, conjugates and pharmaceutically acceptable salts:
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • Ring A and ring B are each independently selected from substituted or unsubstituted C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, 6-14 Member spiroheterocyclyl, 5-11 member bridging heterocyclyl and 4-11 member condensed heterocyclyl; the replacement is 1-4 selected from hydrogen, deuterium, cyano, amino, hydroxyl, halogen, trifluoro Substituents of methyl, trifluoromethoxy, C 1-6 alkyl and C 6-10 aryl.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • Ring A is selected from substituted or unsubstituted C 3-7 cycloalkyl and 3-7 membered heterocycloalkyl.
  • ring A is selected from substituted or unsubstituted C 3-5 cycloalkyl and 3-5 membered heterocycloalkyl.
  • Ring A is selected from substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, and morpholinyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl and C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O and S.
  • Ring B is selected from substituted or unsubstituted phenyl, furyl, thienyl, pyridyl, pyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, tri Azolyl and tetrazolyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl, C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the present invention provides a compound represented by formula I-2-1 or its stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, conjugate and pharmaceutically acceptable Salt:
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • Ring A and ring B are each independently selected from substituted or unsubstituted C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, 6-14 Member spiroheterocyclyl, 5-11 member bridging heterocyclyl and 4-11 member condensed heterocyclyl; the replacement is 1-4 selected from hydrogen, deuterium, cyano, amino, hydroxyl, halogen, trifluoro Substituents of methyl, trifluoromethoxy, C 1-6 alkyl and C 6-10 aryl.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • Ring A is selected from substituted or unsubstituted C 3-7 cycloalkyl and 3-7 membered heterocycloalkyl.
  • ring A is selected from substituted or unsubstituted C 3-5 cycloalkyl and 3-5 membered heterocycloalkyl.
  • Ring A is selected from substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, and morpholinyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl and C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O and S.
  • Ring B is selected from substituted or unsubstituted phenyl, furyl, thienyl, pyridyl, pyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, tri Azolyl and tetrazolyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl, C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the present invention provides a compound represented by formula I-3 or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, conjugates and pharmaceutically acceptable salts:
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • Ring B is selected from substituted or unsubstituted C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, 6-14 membered spiroheterocyclyl, 5-11 member bridged heterocyclic group and 4-11 membered condensed heterocyclic group; the replacement is 1-4 selected from hydrogen, deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethyl Oxygen, C 1-6 alkyl and C 6-10 aryl substituents are substituted.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R 10 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 10 is selected from hydrogen and C 1-3 alkyl.
  • R 10 is selected from hydrogen and methyl.
  • R 11 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 11 is selected from hydrogen and C 1-3 alkyl.
  • R 11 is selected from hydrogen and methyl.
  • each R 12 is independently selected from hydrogen, deuterium, and C 1-6 alkyl.
  • each R 12 is independently selected from hydrogen and C 1-3 alkyl.
  • each R 12 is independently selected from hydrogen and methyl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O and S.
  • Ring B is selected from substituted or unsubstituted phenyl, furyl, thienyl, pyridyl, pyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, tri Azolyl and tetrazolyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl, C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the present invention provides a compound represented by formula I-3-1 or its stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, conjugate and pharmaceutically acceptable Salt:
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • Ring B is selected from substituted or unsubstituted C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, 6-14 membered spiroheterocyclyl, 5-11 member bridged heterocyclic group and 4-11 membered condensed heterocyclic group; the replacement is 1-4 selected from hydrogen, deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethyl Oxygen, C 1-6 alkyl and C 6-10 aryl substituents are substituted.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R 10 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 10 is selected from hydrogen and C 1-3 alkyl.
  • R 10 is selected from hydrogen and methyl.
  • R 11 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 11 is selected from hydrogen and C 1-3 alkyl.
  • R 11 is selected from hydrogen and methyl.
  • each R 12 is independently selected from hydrogen, deuterium, and C 1-6 alkyl.
  • each R 12 is independently selected from hydrogen and C 1-3 alkyl.
  • each R 12 is independently selected from hydrogen and methyl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl.
  • ring B is selected from substituted or unsubstituted C 6-10 aryl and 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O and S.
  • ring B is selected from substituted or unsubstituted phenyl, furyl, thienyl, pyridyl, pyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, tri Azolyl and tetrazolyl.
  • the substitution is 1-4 selected from deuterium, cyano, amino, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl and C 6- 10 aryl substituents are substituted.
  • the substitution is substituted by 1-4 substituents selected from halogen, trifluoromethyl, C 1-6 alkyl.
  • the substitution is by 1-4 substituents selected from fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, n-propyl and isopropyl.
  • the present invention provides a compound represented by formula I-4 or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, conjugates and pharmaceutically acceptable salts:
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • R 13 is selected from hydrogen, deuterium, cyano, halogen, amino, hydroxyl, -NO 2 , C 1-6 alkylamino, C 1-6 alkoxy, substituted or unsubstituted C 1-6 alkyl, C 3-7 cycloalkyl and 3-7 membered heterocycloalkyl; the substitution is by one or more selected from cyano, amino, hydroxyl, halogen, C 1-6 alkyl and C 1-6 alkoxy replaced by substituents;
  • q is any integer of 0 to 4.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R 10 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 10 is selected from hydrogen and C 1-3 alkyl.
  • R 10 is selected from hydrogen and methyl.
  • R 11 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 11 is selected from hydrogen and C 1-3 alkyl.
  • R 11 is selected from hydrogen and methyl.
  • each R 12 is independently selected from hydrogen, deuterium, and C 1-6 alkyl.
  • each R 12 is independently selected from hydrogen and C 1-3 alkyl.
  • each R 12 is independently selected from hydrogen and methyl.
  • R 13 is selected from hydrogen, deuterium, cyano, halogen, amino, hydroxyl, -NO 2 , C 1-3 alkylamino, C 1-3 alkoxy, substituted or unsubstituted C 1-3 alkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl.
  • R 13 is selected from hydrogen, halogen, amino, hydroxyl, -NO 2 and substituted or unsubstituted C 1-3 alkyl.
  • R 13 is selected from hydrogen, fluoro, chloro, bromo, substituted or unsubstituted methyl, ethyl, n-propyl and isopropyl.
  • the substitution is substituted by one or more substituents selected from cyano, amino, hydroxyl, halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • the substitution is substituted by one or more substituents selected from halogen, C 1-3 alkyl and C 1-3 alkoxy.
  • the substitution is with one or more substituents selected from fluoro, chloro, bromo, methyl, ethyl, n-propyl, and isopropyl.
  • q is any integer from 0 to 3.
  • q is any integer from 0-2.
  • q is 1 or 2.
  • the present invention provides a compound represented by formula I-4-1 or its stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, conjugate and pharmaceutically acceptable Salt:
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R is selected from hydrogen, deuterium and C 1-6 alkyl
  • R 7 and R 8 and their connected C atoms and N atoms form unsubstituted or are selected from hydrogen, deuterium, cyano, amino, halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl , C 1-6 alkoxyl, C 6-10 aryl and 5-10 membered heteroaryl substituents substituted 5-7 membered rings;
  • R 13 is selected from hydrogen, deuterium, cyano, halogen, amino, hydroxyl, -NO 2 , C 1-6 alkylamino, C 1-6 alkoxy, substituted or unsubstituted C 1-6 alkyl, C 3-7 cycloalkyl and 3-7 membered heterocycloalkyl; the substitution is by one or more selected from cyano, amino, hydroxyl, halogen, C 1-6 alkyl and C 1-6 alkoxy replaced by substituents;
  • q is any integer of 0 to 4.
  • each R 1 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 1 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R 1 is independently selected from hydrogen.
  • each R 2 is independently selected from hydrogen, deuterium, halogen, and C 1-6 alkyl.
  • each R 2 is independently selected from hydrogen, halogen, and C 1-3 alkyl.
  • each R2 is independently selected from hydrogen.
  • R 5 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 7 is selected from hydrogen and C 1-3 alkyl.
  • R7 is selected from hydrogen
  • R 8 is selected from hydrogen and C 1-3 alkyl.
  • R is selected from hydrogen
  • R 10 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 10 is selected from hydrogen and C 1-3 alkyl.
  • R 10 is selected from hydrogen and methyl.
  • R 11 is selected from hydrogen, deuterium and C 1-6 alkyl.
  • R 11 is selected from hydrogen and C 1-3 alkyl.
  • R 11 is selected from hydrogen and methyl.
  • each R 12 is independently selected from hydrogen, deuterium, and C 1-6 alkyl.
  • each R 12 is independently selected from hydrogen and C 1-3 alkyl.
  • each R 12 is independently selected from hydrogen and methyl.
  • R 13 is selected from hydrogen, deuterium, cyano, halogen, amino, hydroxyl, -NO 2 , C 1-3 alkylamino, C 1-3 alkoxy, substituted or unsubstituted C 1-3 alkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl.
  • R 13 is selected from hydrogen, halogen, amino, hydroxyl, -NO 2 and substituted or unsubstituted C 1-3 alkyl.
  • R 13 is selected from hydrogen, fluoro, chloro, bromo, substituted or unsubstituted methyl, ethyl, n-propyl and isopropyl.
  • the substitution is substituted by one or more substituents selected from cyano, amino, hydroxyl, halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • the substitution is substituted by one or more substituents selected from halogen, C 1-3 alkyl and C 1-3 alkoxy.
  • the substitution is with one or more substituents selected from fluoro, chloro, bromo, methyl, ethyl, n-propyl, and isopropyl.
  • q is any integer from 0 to 3.
  • q is any integer from 0-2.
  • q is 1 or 2.
  • the present invention provides a compound or its stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, conjugate and pharmaceutically acceptable salt thereof, the compound is any of the following kind:
  • the present invention provides a compound or its stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, conjugate and pharmaceutically acceptable salt thereof, the compound is any of the following kind:
  • the present invention also provides a preparation method of the compound shown in formula I, specifically as follows:
  • Step 1 Compound I-2-1 undergoes a condensation reaction with I-2-2 to obtain Compound I-2-3;
  • Step 2 compound 1-2-3 ester group is hydrolyzed under alkaline conditions to obtain compound 1-2-4;
  • Step 3 compound I-2-4 undergoes a condensation reaction with compound I-2-5 to obtain compound I-2-6;
  • Step 4 Compound I-2-6 undergoes removal of the amino protecting group to obtain Compound I-2-7;
  • Step 5 Compound I-2-7 undergoes a condensation reaction with Compound I-2-8 to obtain a compound of formula I;
  • PG is the protecting group of amino, including tert-butoxycarbonyl (t-Boc), benzyloxycarbonyl (CBz), 2-biphenyl-2-propoxycarbonyl (BPoc), phthalimide ( Pht), p-toluenesulfonyl (Tos), trityl (Trt), formyl, trifluoroacetyl, Watt methoxycarbonyl (Fmoc), p-methoxybenzyl (PMB), benzyl (Bn) , Allyloxycarbonyl (Alloc), etc.
  • PG is preferably t-butoxycarbonyl (t-Boc).
  • the present invention also provides a pharmaceutical composition, comprising at least one of the aforementioned compounds or their stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts, and pharmaceutically acceptable acceptable carrier, diluent or excipient.
  • the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.
  • the pharmaceutical composition contains 0.01%-99.99% of the aforementioned compound based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1%-99.9% of the aforementioned compounds. In some embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compounds. In some embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compounds. In some embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compounds.
  • the pharmaceutical composition contains 0.01%-99.99% of a pharmaceutically acceptable carrier, diluent or excipient based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1%-99.9% of a pharmaceutically acceptable carrier, diluent or excipient. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of a pharmaceutically acceptable carrier, diluent or excipient. In certain embodiments, the pharmaceutical composition contains 1%-99% of pharmaceutically acceptable carriers, diluents or excipients. In certain embodiments, the pharmaceutical composition contains 2%-98% of pharmaceutically acceptable carriers, diluents or excipients.
  • All the compounds of the present invention and mixtures, compositions, etc. containing the compounds of the present invention can be administered to a living body through any route of administration.
  • the route of administration can be oral administration, intravenous injection, intramuscular injection, subcutaneous injection, rectal administration, vaginal administration, sublingual administration, nasal cavity inhalation, oral inhalation, eye drops, and local or systemic transdermal administration.
  • All the compounds involved in the present invention and mixtures, compositions, etc. containing the compounds of the present invention can be formulated into a single dose, which contains the active compound of the present invention and carriers, excipients, etc., and the dosage form can be tablets, capsules , injections, granules, powders, suppositories, pills, creams, pastes, gels, powders, oral solutions, inhalants, suspensions, dry suspensions, patches, lotions, etc.
  • These dosage forms may contain ingredients commonly used in pharmaceutical preparations, such as diluents, absorbents, wetting agents, binders, disintegrants, colorants, pH regulators, antioxidants, bacteriostats, isotonic regulators, Anti-sticking agent, etc.
  • Suitable formulations of the above-mentioned various dosage forms can be obtained from public sources, such as Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott Williams & Wilkins published in 2006 and Rowe, Raymond C. Handbook of Pharmaceutical Excipients, Chicago, Pharmaceutical Press in 2005 Published in 2010. Therefore, those skilled in the art can easily prepare.
  • the dosage of the compound of the present invention can be 0.01 to 500 mg/kg per day , the preferred daily dose is 1-100 mg/kg, which can be administered in single or multiple doses.
  • Inhibit virus replication activity preferably inhibit coronavirus activity, particularly preferably inhibit SARS-CoV-2 virus activity;
  • the present invention also provides a method for inhibiting viral replication activity, comprising administering to a subject a therapeutically effective amount of any one of the compounds described above or its stereoisomers, solvates, hydrates, prodrugs, stable isotopes Derivatives, conjugates and pharmaceutically acceptable salts, and/or any of the aforementioned drug conjugates or their stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salt.
  • the virus is a coronavirus, preferably SARS-CoV-2.
  • C 1-6 alkyl alone or in combination means a saturated linear or branched alkyl group containing 1-6, especially 1-4 carbon atoms, including methyl, ethyl, propyl, Isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2- Butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2 -Pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3 ,-Dimethyl-2-butyl and so on.
  • C 1-6 alkyl is any one of methyl, ethyl, isopropyl and tert-butyl.
  • Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, said substituents being preferably one or more of the following groups independently selected from alkyl radical, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy group, heterocycloalkoxy group, cycloalkylthio group, heterocycloalkylthio group, oxo group, carboxyl group or carboxylate group.
  • C 3-7 cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, which means a saturated cycloalkyl group having 3 to 7, especially 3-6 carbon atoms, including Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
  • Particular “C 3-7 cycloalkyl” is cyclopropyl, cyclopentyl, cyclohexyl and the like.
  • C 3-5 cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, which represents a saturated cycloalkyl group with 3 to 5 carbon atoms, including cyclopropyl, cyclobutyl , cyclopentyl, etc.
  • C 1-6 alkoxy alone or in combination denotes the group C 1-6 alkyl-O-, wherein “C 1-6 alkyl” denotes as defined above.
  • C 1-6 alkylamino alone or in combination denotes the group C 1-6 alkyl-NH-, wherein “C 1-6 alkyl” denotes as defined above.
  • heterocycloalkyl refers to a saturated or partially unsaturated (containing 1 or 2 double bonds) non-aromatic cyclic group composed of carbon atoms and heteroatoms such as nitrogen, oxygen or sulfur, which can be It is a monocyclic or bicyclic group.
  • the number of heteroatoms in the heterocycloalkyl group is preferably 1, 2, 3 or 4, and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl group can be optionally oxidized.
  • the hydrogen atoms on the "heterocycloalkyl” are independently optionally substituted with one or more substituents described herein.
  • a “heterocycloalkyl” may be attached to the parent molecule through any ring atom in the ring.
  • 3-7 membered heterocycloalkyl refers to a monocyclic heterocycloalkyl group containing 3-7 carbon atoms and heteroatoms; for example, aziridinyl, azetidinyl, oxetanyl, pyrrole Alkyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxothiomorpholinyl.
  • 5-6 membered heterocycloalkyl refers to a monocyclic heterocycloalkyl group containing 5-6 carbon atoms and heteroatoms; for example, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholine thiomorpholinyl, tetrahydropyranyl, 1,1-dioxothiomorpholinyl.
  • 6-14 membered spiroheterocyclic group refers to 6 to 14 members, a polycyclic heterocyclic group sharing one atom (called spiro atom) between monocyclic rings, wherein one or more ring atoms are selected from nitrogen, oxygen and sulfur heteroatoms, said sulfur optionally being oxo-substituted (ie to form sulfoxides or sulfones), with the remaining ring atoms being carbon. It may contain one or more double bonds. More preferably 7 to 10 yuan (eg 7, 8, 9 or 10 yuan).
  • the spiroheterocyclyl can be divided into single spiroheterocyclyl, double spiroheterocyclyl or polyspiroheterocyclyl, preferably single spiroheterocyclyl and double spiroheterocyclyl. More preferably, it is a 3-membered/5-membered, 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocyclic group.
  • spiroheterocyclyls include:
  • 4-11 membered fused heterocyclic group refers to a 4 to 11-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain One or more double bonds in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, said sulfur optionally being oxo-substituted (i.e. to form sulfoxides or sulfones), and the remaining ring atoms being carbon . More preferably 7 to 10 yuan (eg 7, 8, 9 or 10 yuan).
  • bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups preferably bicyclic or tricyclic, more preferably 3-membered/4-membered, 3-membered/5-membered, 3-membered/6-membered , 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/6 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan 5-membered and 6-membered/6-membered bicyclic condensed heterocyclic groups.
  • fused heterocyclic groups include:
  • 5-11 membered bridged heterocyclic group refers to a 5 to 11-membered polycyclic heterocyclic group that any two rings share two atoms that are not directly connected, which may contain one or more double bonds, one or A number of ring atoms are heteroatoms selected from nitrogen, oxygen and sulfur, said sulfur being optionally substituted with oxo (ie to form sulfoxides or sulfones), and the remainder of the ring atoms being carbon.
  • it is 6 to 11 yuan, more preferably 7 to 10 yuan (eg 7, 8, 9 or 10 yuan).
  • bridged heterocyclyl groups include:
  • C 6-10 aryl refers to a 6 to 10 membered all-carbon monocyclic or fused polycyclic (a fused polycyclic is a ring that shares adjacent pairs of carbon atoms) group with a conjugated ⁇ -electron system, such as benzene base and naphthyl.
  • the aryl ring includes an aryl ring as described above fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is an aryl ring, non-limiting examples of which include :
  • Aryl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, preferably the substituents are independently optionally selected from halogen, alkyl, alkoxy, haloalkane one of radical, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl or multiple substituents.
  • 5-10 membered heteroaryl refers to a heteroaromatic system containing 1 to 4 (eg 1, 2, 3 and 4) heteroatoms, 5 to 10 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen, (for example 5, 6, 7, 8, 9 or 10 members), more preferably 5 or 6 members, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl , pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc.
  • 1 to 4 eg 1, 2, 3 and 4
  • heteroatoms selected from oxygen, sulfur and nitrogen, (for example 5, 6, 7, 8, 9 or 10 members), more preferably 5 or 6 members, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl ,
  • the heteroaryl ring includes a heteroaryl as described above fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which include :
  • Heteroaryl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, preferably the substituents are independently optionally selected from halogen, alkyl, alkoxy, One of haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl or multiple substituents.
  • benzo C 5-7 cycloalkyl means that a phenyl group and a C 5-7 cycloalkyl group form a ring, and the structure is: Wherein, n is 1, 2 or 3, meanwhile, benzo C 5-7 cycloalkyl can be that phenyl is connected with connection position, also can be that C 5-7 cycloalkyl is connected with connection position; and benzene And the C 5-7 cycloalkyl can be either substituted by phenyl or C 5-7 cycloalkyl.
  • amino alone or in combination denotes a primary (-NH 2 ), secondary (-NH-) or tertiary amino group
  • halogen alone or in combination means fluorine, chlorine, bromine or iodine. Especially fluorine, chlorine or bromine.
  • cyano alone or in combination refers to the group -CN.
  • hydroxyl alone or in combination refers to the group -OH.
  • aldehyde alone or in combination refers to the group -CHO.
  • substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms are independently substituted by the corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions and that a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (eg, ethylenic) bond.
  • the bond configuration is not specified, i.e. the key can be or or both and Two configurations.
  • stereoisomer refers to compounds that have the same chemical structure but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric (cis/trans) isomers, atropisomers, and the like.
  • isotopically derivative refers to compounds that differ in structure only by the presence of one or more isotopically enriched atoms.
  • hydrogen is replaced by "deuterium” or “tritium”, or 18 F-fluorine label ( 18 F isotope) is used instead of fluorine, or 11 C-, 13 C-, or 14 C-enriched
  • carbon atoms 11 C-, 13 C-, or 14 C-carbon labels; 11 C-, 13 C-, or 14 C-isotopes
  • Such compounds are useful, for example, as analytical tools or probes in biological assays, or as tracers for in vivo diagnostic imaging of disease, or as tracers for pharmacodynamic, pharmacokinetic or receptor studies.
  • the various deuterated forms of the compounds of the present invention mean that each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can refer to the relevant literature to synthesize the deuterated form of the compound.
  • deuterated starting materials can be used in the preparation of deuterated forms of the compounds, or they can be synthesized using conventional techniques using deuterated reagents including but not limited to deuterated borane, trideuterioborane in tetrahydrofuran , deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
  • Deuterated compounds generally retain comparable activity to undeuterated compounds, and can achieve better metabolic stability when deuterated at certain sites, thereby gaining certain therapeutic advantages.
  • pharmaceutically acceptable salt means that the compounds of the present invention exist in the form of their pharmaceutically acceptable salts, including acid addition salts and base addition salts.
  • Pharmaceutically acceptable salts are described in pharmaceutically salts by SM Berge in J. Pharmaceutical Sciences (Vol. 66: 1-19, 1977).
  • the pharmaceutically acceptable non-toxic acid addition salt means the salt formed by the compound in the present invention and organic or inorganic acid
  • organic or inorganic acid includes but not limited to hydrochloric acid, sulfuric acid, hydrobromic acid, hydrogen iodide Acid, phosphoric acid, nitric acid, perchloric acid, acetic acid, oxalic acid, maleic acid, fumaric acid, tartaric acid, benzenesulfonic acid, methanesulfonic acid, salicylic acid, succinic acid, citric acid, lactic acid, propionic acid, benzoic acid, p-toluenesulfonic acid, malic acid, etc.
  • Non-toxic base addition salts refer to salts formed by the compounds of the present invention with organic or inorganic bases, including but not limited to alkali metal salts such as lithium, sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; organic base salts, such as ammonium salts or N + (C 1-6 alkyl) 4 salts formed by organic bases containing N groups.
  • alkali metal salts such as lithium, sodium or potassium salts
  • alkaline earth metal salts such as calcium or magnesium salts
  • organic base salts such as ammonium salts or N + (C 1-6 alkyl) 4 salts formed by organic bases containing N groups.
  • solvate refers to the physical association of a compound of the present invention with one or more, preferably 1-3, solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In some cases, for example, when one or more, preferably 1-3, solvent molecules are incorporated in the crystal lattice of a crystalline solid, solvates will be isolated. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.
  • prodrug refers to a compound that can be transformed in vivo under physiological conditions, for example by hydrolysis in blood, to yield the active prodrug.
  • pharmaceutical composition means a mixture containing one or more compounds described herein or a physiologically/pharmaceutically acceptable salt or prodrug thereof and other chemical components, and other components such as physiologically/pharmaceutically acceptable Carriers and Excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • Example 1 Intermediate tert-butyl ((S)-1-((1R,2S,5S)-2-((S)-1-amino-1-oxo-3-((S)-2- Oxypyrrolidin-3-yl)propan-2-yl)carbamoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-3-yl)-3,3-di Preparation of methyl-1-oxobutan-2-yl) carbamate (intermediate A)
  • Step 1 tert-butyl ((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)carbamate (intermediate Preparation of body 2-2)
  • Step 2 Preparation of (S)-2-amino-3-((S)-2-oxopyrrolidin-3-yl)propionamide hydrochloride (intermediate 2-3)
  • Step 3 Methyl(1R,2S,5S)-3-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutyryl)-6,6-dimethyl Preparation of methyl-3-azabicyclo[3.1.0]hexane-2-carboxylate (intermediate 2-5)
  • Step 4 (1R,2S,5S)-3-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutyryl)-6,6-dimethyl- Preparation of 3-azabicyclo[3.1.0]hexane-2-carboxylic acid (intermediate 2-6)
  • Step 5 tert-butyl ((S)-1-((1R,2S,5S)-2-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrole Alkyl-3-yl)propan-2-yl)carbamoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl)-3,3-dimethyl Preparation of -1-oxobutan-2-yl) carbamate (intermediate 2-7)
  • Step 6 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-amino-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide salt
  • (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-amino-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide salt Preparation of acid salt (intermediate A)
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-((1R,2R)-2-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxamide)-3,3-dimethylbutyryl)
  • Preparation of -6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 3-1)
  • Step 2 (1R,2S,5S)-3-(2-((1R,2R)-2-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxamide)-3,3- Dimethylbutyryl)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-6,6-dimethyl-3-
  • azabicyclo[3.1.0]hexane-2-carboxamide hydrochloride compound 3
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-(cyclopropanylamino)-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-
  • 2-formamide compound 4-1
  • Step 2 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S )-2-(cyclopropanecarboxamide)-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 4 ) preparation.
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-((1S,2S)-2-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxamide)-3,3-dimethylbutyryl)
  • Preparation of -6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 5-1)
  • Step 2 (1R,2S,5S)-3-(2-((1S,2S)-2-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxamide)-3,3- Dimethylbutyryl)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-6,6-dimethyl-3-
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[ 3.1.0]
  • hexane-2-carboxamide compound 7-2
  • Step 2 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S )-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-
  • 2-formamide compound 7
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[ 3.1.0]
  • hexane-2-carboxamide compound 8-1)
  • Step 2 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S )-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-
  • 2-formamide compound 8
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((R)-3,3-Dimethyl-2-(1-(trifluoromethyl)cyclopropane-1-carboxamido)butyryl)-6,6-dimethyl-3 -Preparation of azabicyclo[3.1.0]hexane-2-carboxamide (compound 9-1)
  • Step 2 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S )-3,3-Dimethyl-2-(1-(trifluoromethyl)cyclopropane-1-carboxamido)butyryl)-6,6-dimethyl-3-azabicyclo[3.1. 0]
  • hexane-2-carboxamide compound 9
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-3,3-Dimethyl-2-((1R,2R)-2-phenylcyclopropane-1-carboxamido)butyryl)-6,6-dimethyl -
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-3,3-Dimethyl-2-((1R,2R)-2-phenylcyclopropane-1-carboxamido)butyryl)-6,6-dimethyl -
  • 3-azabicyclo[3.1.0]hexane-2-carboxamide compound 10-1
  • Step 2 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S )-3,3-dimethyl-2-((1R,2R)-2-phenylcyclopropane-1-carboxamido)butyryl)-6,6-dimethyl-3-azabicyclo[ 3.1.0]
  • hexane-2-carboxamide compound 10
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-3,3-dimethyl-2-((1R,2S)-2-phenylcyclopropane-1-carboxamido)butyryl)-6,6-dimethyl -
  • Step 1 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl )-3-((S)-3,3-dimethyl-2-((1R,2S)-2-phenylcyclopropane-1-carboxamido)butyryl)-6,6-dimethyl -
  • 3-azabicyclo[3.1.0]hexane-2-carboxamide compound 11-1)
  • Step 2 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S )-3,3-dimethyl-2-((1R,2S)-2-phenylcyclopropane-1-carboxamido)butyryl)-6,6-dimethyl-3-azabicyclo[ 3.1.0]
  • Preparation of hexane-2-carboxamide (compound 11)
  • Step 2 Preparation of ethyl (1S,2S) or (1R,2R)-2-(4-fluorophenyl)cyclopropane-1-carboxylate (compound 12-3)
  • Step 3 Preparation of (1S,2S) or (1R,2R)-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid (compound 12-4)
  • Step 4 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2- Base)-3-((S)-2-((1R,2R) or (1S,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxamido)-3,3-dimethyl Preparation of butyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 12-4)
  • Step 5 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-(( S)-2-((1R,2R)-2-(4-fluorophenyl)cyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl- Preparation of 3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 12)
  • Step 2 Preparation of ethyl (1R,2R)-2-(2-chlorophenyl)cyclopropane-1-carboxylate (compound 14-3)
  • Step 5 (1R,2S,5S)-3-((S)-2-((1R,2R)-2-(2-chlorophenyl)cyclopropane-1-carboxamido)-3,3 -Dimethylbutyryl)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-6,6-dimethyl- Preparation of 3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 14)
  • Step 2 Preparation of ethyl (1R,2R)-2-(3,4-difluorophenyl)cyclopropane-1-carboxylate (compound 15-3)
  • Step 3 Preparation of (1R,2R)-2-(3,4-difluorophenyl)cyclopropane-1-carboxylic acid (compound 15-4)
  • Step 4 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2- Base)-3-((S)-2-((1R,2R)-2-(3,4-difluorophenyl)cyclopropane-1-carboxamido)-3,3-dimethylbutyryl )-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-formamide (compound 15-5)
  • Step 2 Preparation of ethyl (1S,2S) or (1R,2R)-2-(4-chlorophenyl)cyclopropane-1-carboxylate (compound 16-3)
  • Step 3 Preparation of (1S,2S) or (1R,2R)-2-(4-chlorophenyl)cyclopropane-1-carboxylic acid (compound 16-4)
  • Step 4 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2- Base)-3-((S)-2-((1R,2R) or (1S,2S)-2-(4-chlorophenyl)cyclopropane-1-carboxamido)-3,3-dimethyl Preparation of butyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 16-4)
  • Step 5 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-(( S)-2-((1R,2R)-2-(4-chlorophenyl)cyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl- Preparation of 3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 16)
  • Step 2 Preparation of (1S,2S) or (1R,2R)-2-(2-bromophenyl)cyclopropane-1-carboxylic acid ethyl ester (compound 17-3)
  • Step 3 Preparation of (1S,2S) or (1R,2R)-2-(2-bromophenyl)cyclopropane-1-carboxylic acid (compound 17-4)
  • Step 4 (1R,2S,5S)-N-((S)-1-amino-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2- Base)-3-((S)-2-((1R,2R) or (1S,2S)-2-(2-bromophenyl)cyclopropane-1-carboxamido)-3,3-dimethyl Preparation of butyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 17-4)
  • Step 5 (1R, 2S, 5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-(( S)-2-((1R,2R)-2-(2-bromophenyl)cyclopropane-1-carboxamido)-3,3-dimethylbutyryl)-6,6-dimethyl- Preparation of 3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 17)
  • Step 1 (S)-2-((1R,2S,5S)-3-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutyryl)-6 , the preparation of 6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamido) (compound 18-1)
  • Step 2 (S)-2-((1R,2S,5S)-3-((S)-2-Amino-3,3-dimethylbutyryl)-6,6-dimethyl-3 -
  • Step 3 (S)-2-((1R,2S,5S)-3-((R)-3,3-Dimethyl-2-(1R,2R)-2-phenylcyclopropane-1 Preparation of -formamido)butyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide) (compound 18-3)
  • Step 4 (1R,2S,5S)-3-((R)-3,3-Dimethyl-2-((1R,2R)-2-phenylcyclopropane-1-carboxamido)butyl Acyl)-N-((S)-1-hydroxy-3-(S)-2-oxopyrrolidin-3-yl)propan-2-yl)-6,6-dimethyl-3-aza Preparation of bicyclo[3.1.0]hexane-2-carboxamide (compound 18-4)
  • triethyl phosphoroacetate (10.05 g, 44.83 mmol) was added to a solution of sodium hydride (1.66 g, 41.38 mmol) in toluene (80 ml) and vigorously stirred for 10 min, followed by addition of S-propylene oxide (2.00 g , 34.48mmol) and stirred at room temperature for 6h. Then 30% sodium hydroxide (30ml) was added and stirred at reflux for 2h. After completion, it was cooled to room temperature, the aqueous phase was taken out by separation, and the mixture was quenched by adjusting the pH of the solution to 2-3 with HCl, and extracted three times with EA (100 mL).
  • Step 2 (2S)-2-((1R,2S,5S)-3-((2S,3,3-Dimethyl-2-(2R)-2-methylcyclopropane-1-carboxamide Preparation of butyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (compound 19-3)
  • Step 3 (1R,2S,5S)-3-((2S)-3,3-Dimethyl-2-((2R)-2-methylcyclopropane-1-carboxamido)butyryl) -N-((S)-1-hydroxy-3-(S)-2-oxopyrrolidin-3-yl)propan-2-yl)-6,6-dimethyl-3-azabicyclo[ 3.1.0]
  • Preparation of hexane-2-carboxamide compound 19-4)
  • Step 4 1R,2S,5S)-3-((S)-3,3-Dimethyl-2-((1R,2R)-2-methylcyclopropane-1-carboxamido)butyryl )-6,6-Dimethyl-N-((R)-1-oxo-3-(S)-2-oxopyrrolidin-3-yl)propan-2-yl)-3-aza Preparation of bicyclo[3.1.0]hexane-2-carboxamide (compound 19)
  • Step 1 Methyl (S)-2-((1R,2S,5S)-3-(S)-2-((1R,2R)-2-(4-bromo-3-fluorophenyl) ring Propane-1-carboxamido)-3,3-dimethylbutanol)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamido)- Preparation of 3-((S)-2-oxopyrrolidin-3-yl)propionate
  • Step 2 (1R,2S,5S)-3-((S)-2-((1R,2R)-2-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxamide)- 3,3-Dimethylbutyryl)-n-(S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-6,6- Preparation of Dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
  • Step 3 (1R,2S,5S)-3-((S)-2-((1R,2R)-2-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxamide)- 3,3-Dimethylbutyryl)-6,6-dimethyl-n-(S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propane- Preparation of 2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide
  • Embodiment 19 SARS-CoV-2 3CL enzyme inhibition experiment
  • the wavelength of excitation light is 340nm, and the wavelength of emission light is 490nm.
  • the calculated inhibition rate was used to fit the inhibition curve with log (inhibitor) vs. response-Variable slope (four parameters) in the Nonlinear regression (curve fit) function of GraphPad Prism 8 software, and calculate the IC 50 value.
  • the compounds in the list all show good inhibitory activity of SARS-CoV-2 3CL enzyme, all at nM level. Among them, compounds 3, 4, 14, 16, and 18 had better activities than PF-07321332; compounds 7, 8, 9, 17, and 19 had comparable enzyme inhibitory activities to PF-07321332.
  • Coronavirus OC43 coronavirus OC43, CoV-OC43
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • MRC-5 cells were digested, diluted with DME medium containing 2% FBS and 1% P/S to 2 ⁇ 10 5 /mL, 50 ⁇ L per well was inoculated in a 96-well plate, and cultured overnight in an incubator.
  • Inhibition rate (measured sample value-average value of virus control group)/(average value of cell control group-average value of virus control group).
  • the calculated inhibition rate was used to fit the inhibition curve with log(inhibitor)vs.response--Variable slope(four parameters) in the Nonlinear regression(curve fit) function of GraphPad Prism 8 software, and the EC 50 value was calculated.
  • the compounds in the list all exhibit excellent anti-OC43 coronavirus activity in MDCK cells, and the compound activities are all at the nM level.
  • Compounds 3, 10, 14, 16, and 17 all have better antiviral activity than the reference positive molecule PF-07321332.
  • mice information Purchase ICR (CD-1) female mice from Zhejiang VT-River Company, weighing between 20-30g.
  • test compound was administered PO to 3 mice, and blood was collected at 0.083, 0.25, 0.5, 1, 2, 4 and 8 hours for testing.
  • test compound was administered at 10 mg/kg.
  • HPLC Pump Shimadzu LC-30AD; Kinetex 2.6 ⁇ m C18 100A column(50mm*2.1mm);
  • Mobile phase mobile phase A: W water (0.1% FA), mobile phase B: acetonitrile (0.1% FA);
  • K2EDTA is used as an anticoagulant; add 2 ⁇ L of methanol to all samples, add 200 ⁇ L of acetonitrile containing 100 ng/mL IS (Tolbutamide), vortex for 1 minute, and centrifuge at 4000 rpm for 15 minutes. Take the supernatant.
  • IS Tolbutamide
  • the positive molecule PF-07321332 (CAS: 2628280-40-8) was purchased from Shanghai Xingmo (lot number: XM211031-1).
  • the drug concentrations of the test compounds in plasma were as follows:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé représenté par la formule I ou un stéréoisomère, un solvate, un hydrate, un promédicament, un dérivé isotopique stable, un conjugué et un sel pharmaceutiquement acceptable de celui-ci. Le composé et le conjugué de médicament ont une excellente activité dans l'inhibition de la protéase 3CL du coronavirus SARS-CoV-2 et peuvent être utilisés pour prévenir et traiter la pneumonie provoquée par une infection à coronavirus SARS-CoV-2.
PCT/CN2022/143566 2021-12-31 2022-12-29 Composé pour prévenir et traiter une infection à coronavirus, conjugué de celui-ci et méthode associée WO2023125846A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280085522.9A CN118434728A (zh) 2021-12-31 2022-12-29 用于预防和治疗冠状病毒感染的化合物及其偶联物和方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111677918 2021-12-31
CN202111677918.6 2021-12-31
CN202210287055 2022-03-22
CN202210287055.X 2022-03-22

Publications (1)

Publication Number Publication Date
WO2023125846A1 true WO2023125846A1 (fr) 2023-07-06

Family

ID=86998032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/143566 WO2023125846A1 (fr) 2021-12-31 2022-12-29 Composé pour prévenir et traiter une infection à coronavirus, conjugué de celui-ci et méthode associée

Country Status (3)

Country Link
CN (1) CN118434728A (fr)
TW (1) TW202334123A (fr)
WO (1) WO2023125846A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (fr) * 2004-12-09 2006-06-15 Pfizer Inc. Compositions et composes anti-coronaviraux, leur utilisation pharmaceutique et materiaux destines a leur synthese
WO2021252644A1 (fr) * 2020-06-09 2021-12-16 Pardes Biosciences, Inc. Inhibiteurs de cystéine protéases et leurs procédés d'utilisation
WO2021250648A1 (fr) * 2020-09-03 2021-12-16 Pfizer Inc. Composés antiviraux contenant du nitrile
WO2022020242A1 (fr) * 2020-07-20 2022-01-27 Enanta Pharmaceuticals, Inc. Peptides fonctionnalisés en tant qu'agents antiviraux
CN114149415A (zh) * 2021-07-26 2022-03-08 中国药科大学 一种拟肽类化合物及其衍生物、制备方法、药物组合物和应用
WO2022251615A1 (fr) * 2021-05-28 2022-12-01 Arun K Ghosh Composés pour le traitement du sras
WO2022256434A1 (fr) * 2021-06-02 2022-12-08 ACEA Therapeutics, Inc. Inhibiteurs de protéase utilisés comme antiviraux
WO2023283256A1 (fr) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Composés anti-viraux

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (fr) * 2004-12-09 2006-06-15 Pfizer Inc. Compositions et composes anti-coronaviraux, leur utilisation pharmaceutique et materiaux destines a leur synthese
WO2021252644A1 (fr) * 2020-06-09 2021-12-16 Pardes Biosciences, Inc. Inhibiteurs de cystéine protéases et leurs procédés d'utilisation
WO2022020242A1 (fr) * 2020-07-20 2022-01-27 Enanta Pharmaceuticals, Inc. Peptides fonctionnalisés en tant qu'agents antiviraux
WO2021250648A1 (fr) * 2020-09-03 2021-12-16 Pfizer Inc. Composés antiviraux contenant du nitrile
WO2022251615A1 (fr) * 2021-05-28 2022-12-01 Arun K Ghosh Composés pour le traitement du sras
WO2022256434A1 (fr) * 2021-06-02 2022-12-08 ACEA Therapeutics, Inc. Inhibiteurs de protéase utilisés comme antiviraux
WO2023283256A1 (fr) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Composés anti-viraux
CN114149415A (zh) * 2021-07-26 2022-03-08 中国药科大学 一种拟肽类化合物及其衍生物、制备方法、药物组合物和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CITARELLA ANDREA, SCALA ANGELA, PIPERNO ANNA, MICALE NICOLA: "SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors", BIOMOLECULES, M D P I AG, CH, vol. 11, no. 4, 19 April 2021 (2021-04-19), CH , pages 607, XP055869885, ISSN: 2218-273X, DOI: 10.3390/biom11040607 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
CN118434728A (zh) 2024-08-02
TW202334123A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
US11319319B1 (en) Compounds for inhibiting NLRP3 and uses thereof
BR112021022419B1 (pt) Compostos antivirais contendo nitrila e composição farmacêutica
WO2023125846A1 (fr) Composé pour prévenir et traiter une infection à coronavirus, conjugué de celui-ci et méthode associée
WO2022143473A1 (fr) Composé nucléosidique et son utilisation
TW202115076A (zh) 嘧啶并五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
BR112020022936A2 (pt) derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
CN101723936B (zh) 激酶抑制剂及其在药学中的用途
WO2021151265A1 (fr) Utilisation pharmaceutique d'un composé à base d'aldéhyde
UA126394C2 (uk) Похідні бензоксазолу як імуномодулятори
PT2873665T (pt) Compostos antivirais
TWI762769B (zh) 肽醯精胺酸脫亞胺酶抑制劑及其用途
MX2007001054A (es) Imidazo[4,5-d]pirimidinas, sus usos y metodos de preparacion.
WO2023280280A1 (fr) Composé à cycle fusionné agissant en tant qu'inhibiteur de kras g12d
CN107922353A (zh) Ido抑制剂
IL310117A (en) A ketoamide derivative and its use
WO2021223718A1 (fr) Composés du groupe des aldéhydes, leur procédé de préparation, composition pharmaceutique et utilisation associées
TW200304817A (en) Chemical compounds
ES2381180T3 (es) Utilización de derivados de indol como activadores de nurr-1, para el tratamiento de la enfermedad de parkinson
WO2023011443A1 (fr) Inhibiteur à petites molécules de protéase 3cl pour traiter ou prévenir une infection à coronavirus et son utilisation
CA3016087A1 (fr) Composes inhibiteurs de cyclophilines et leurs utilisations
WO2023272571A1 (fr) Utilisation médicale d'un dérivé de 2,3-époxysuccinyle
WO2023227117A1 (fr) Inhibiteur de protéase de type 3c
WO2021238834A1 (fr) Composé arylformamide et son procédé de préparation et son utilisation médicale
CA3197092A1 (fr) Derives de 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide utilises en tant qu'inhibiteurs de vhl pour le traitement de l'anemie et du cance
WO2024078618A1 (fr) Forme cristalline d'un composé polypeptidique substitué par cyano et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22915095

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE